Cargando…
Recent advances and emerging therapies in anaplastic thyroid carcinoma
Anaplastic thyroid cancer is a rare and aggressive thyroid cancer with an overall survival measured in months. Because of this poor prognosis and often advanced age at presentation, these patients have traditionally been treated palliatively and referred for hospice. However, recent progress using n...
Autores principales: | Cabanillas, Maria E., Zafereo, Mark, Williams, Michelle D., Ferrarotto, Renata, Dadu, Ramona, Gross, Neil, Gunn, G. Brandon, Skinner, Heath, Cote, Gilbert, Grosu, Horiana B., Iyer, Priyanka, Busaidy, Naifa L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753603/ https://www.ncbi.nlm.nih.gov/pubmed/31583077 http://dx.doi.org/10.12688/f1000research.13124.1 |
Ejemplares similares
-
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018) -
OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility
por: Cabanillas, Maria, et al.
Publicado: (2019) -
Circulating BRAF V600E Cell-Free DNA as a Biomarker
in the Management of Anaplastic Thyroid Carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018) -
Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma
por: Wang, Jennifer Rui, et al.
Publicado: (2022) -
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma
por: Wang, Jennifer R., et al.
Publicado: (2019)